ProQR Therapeutics N.V.

Factors to consider:

• Total employees count: 59 as of 2014
• Price in estimated range
• Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

• 2024-12-31 to 2025-12-31 estimated range: [1.66$, 3.78$]
• 2025-12-31 to 2026-12-31 estimated range: [1.59$, 3.63$]

Financial Metrics affecting the PRQR estimates:

• Positive: with PPE of -7.8 at the end of fiscal year the price was low
• Negative: negative Operating income
• Negative: Operating cash flow per share per price, % of -17.48 <= 0.33
• Positive: -4.48 < Investing cash flow per share per price, % of -1.96
• Positive: 41.86 < Shareholder equity ratio, % of 52.73 <= 63.39
• Negative: negative Net income